Personalized mRNA Cancer Vaccine Reduces Melanoma Recurrence by 42 Percent

OPA WIRE, Oct 23 (OPA) — A landmark clinical trial has revealed that the personalized mRNA vaccine intismeran reduces the risk of melanoma recurrence or death by 42 percent compared to standard immunotherapy treatments. The study, which involved 1,137 patients across 157 international sites, focused on individuals who had undergone surgery for high-risk melanoma but had not received prior drug treatment. Patients received the vaccine in combination with pembrolizumab, an immunotherapy drug marketed as Keytruda, to test the efficacy of targeting unique tumor neoantigens.

Professor Georgina Long, medical director of the Melanoma Institute Australia and principal investigator, described the results as a fundamental change in cancer care. "These results show that patients with earlier-stage melanoma can be treated after surgery in a fundamentally new way," Long said. The vaccine is developed by Moderna and MSD and functions by training the immune system to identify and attack cancer cells based on the specific genetic profile of a patient’s tumor, a process Long compared to the transformative impact of early digital communication.

The trial included several Australian medical institutions, such as Westmead Hospital, the Princess Alexandra Hospital, and the Peter MacCallum Cancer Centre. Associate Professor Seth Cheetham, director of the Australian mRNA Cancer Vaccine Hub, noted that the study provides definitive evidence that mRNA technology improves outcomes compared to the current standard of care. The research represents the first large-scale validation of this personalized approach in a clinical setting, confirming the potential for immune-based therapies to address high-risk malignancies.

While the current findings are specific to melanoma, researchers anticipate the technology could eventually be adapted for other cancer types, including lung, kidney, and head and neck cancers. The success of the trial has drawn significant attention to the potential of mRNA platforms in oncology, with pharmaceutical developers continuing to analyze the long-term data. The research builds on previous advancements in immunotherapy, aiming to establish a new gold standard for post-surgical cancer treatment protocols globally.